{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:26:20Z","timestamp":1792452380860,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11910-018-0848-0","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T04:06:00Z","timestamp":1527048360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["The Sleep Disorder in Anti-lgLON5 Disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Carles","family":"Gaig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Iranzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Graus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","volume":"13","author":"L Sabater","year":"2014","unstructured":"\u2022\u2022 Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575\u201386. In this paper the disease is identified and described for first time.","journal-title":"Lancet Neurol"},{"key":"848_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","volume":"88","author":"C Gaig","year":"2017","unstructured":"\u2022\u2022 Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736\u201343. The clinical presentation of the disease is described in detail in a series of 22 patients.","journal-title":"Neurology"},{"key":"848_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","volume":"132","author":"E Gelpi","year":"2016","unstructured":"\u2022\u2022 Gelpi E, H\u00f6ftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132:531\u201343. The neuropathological features of the disease are described in detail and neuropathological criteria for anti-IgLON5 disease are defined.","journal-title":"Acta Neuropathol"},{"key":"848_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","volume":"87","author":"A Sonderen van","year":"2016","unstructured":"van Sonderen A, Ari\u00f1o H, Petit-Pedrol M, Leypoldt F, K\u00f6rtv\u00e9lyessy P, Wandinger KP, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87:521\u20138.","journal-title":"Neurology"},{"key":"848_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853\u201364.","journal-title":"Mov Disord"},{"key":"848_CR6","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(15)60445-7","volume":"385","author":"B H\u00f6gl","year":"2015","unstructured":"\u2022 H\u00f6gl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385:1590. Report of the first patient after the initial description of the disease.","journal-title":"Lancet"},{"key":"848_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2014.08.027","volume":"275","author":"R Bahtz","year":"2014","unstructured":"Bahtz R, Teegen B, Borowski K, Probst C, Bl\u00f6cker IM, Fechner K, et al. Autonatibodies against IgLON5: two new cases. J Neuroimmunol. 2014;275:8.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"848_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000302","volume":"4","author":"JB Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e302.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"848_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2016.09.012","volume":"300","author":"R Haitao","year":"2016","unstructured":"Haitao R, Yingmai Y, Yan H, Fei H, Xia L, Honglin H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9\u201310.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"848_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000383","volume":"4","author":"M Bonello","year":"2017","unstructured":"Bonello M, Jacob A, Ellul MA, Barker E, Parker R, Jefferson S, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e383.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"848_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.019","volume":"310","author":"R Haitao","year":"2017","unstructured":"Haitao R, Huiqin L, Tao Q, Xunzhe Y, Xiaoqiu S, Wei L, et al. Autoimmune encephalitis associated with vitiligo? J Neuroimmunol. 2017;310:14\u20136.","journal-title":"J Neuroimmunol"},{"key":"848_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JND-170259","volume":"4","author":"S Wenninger","year":"2017","unstructured":"Wenninger S. Expanding the clinical Spectrum of IgLON5-syndrome. J Neuromuscul Dis. 2017;4:337\u20139.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"848_CR13","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","volume":"4","author":"JA Honorat","year":"2017","unstructured":"\u2022 Honorat JA, Lomorowski L, Josephs KA, et al. IgLON5 antibody. Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e385. Description of another series of 20 patients with antibodies against IgLON5.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"848_CR14","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1212\/NXI.0000000000000136","volume":"2","author":"MM Simabukuro","year":"2015","unstructured":"\u2022 Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136. Additional description of a patient with anti-IgLON5 antibodies and progressive disease course.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"848_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mds.26608","volume":"31","author":"N Br\u00fcggemann","year":"2016","unstructured":"\u2022 Br\u00fcggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31:762\u20134. Description of a patient with atypical clinical features.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"848_CR16","first-page":"710","volume":"30","author":"MT Montojo","year":"2015","unstructured":"Montojo MT, Piren V, Benkhadra F, et al. Mimicking progressive supranuclear palsy and causing Tako-Tsubo syndrome: a case report on IgLON5 encephalopathy [abstract]. Mov Disord. 2015;30(Suppl 1):710.","journal-title":"Mov Disord"},{"key":"848_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/sleep\/28.2.203","volume":"28","author":"A Iranzo","year":"2005","unstructured":"Iranzo A, Santamar\u00eda J. Severe obstructive sleep apnea\/hypopnea mimicking REM sleep behavior disorder. Sleep. 2005;28:203\u20136.","journal-title":"Sleep"},{"key":"848_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.sleep.2006.01.001","volume":"7","author":"M Zucconi","year":"2006","unstructured":"Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med. 2006;7:175\u201383.","journal-title":"Sleep Med"},{"key":"848_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/sleep\/14.1.69","volume":"14","author":"MW Mahowald","year":"1991","unstructured":"Mahowald MW, Schenck CH. Status dissociatus: a perspective on states of being. Sleep. 1991;14:69\u201379.","journal-title":"Sleep"},{"key":"848_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1388-2457(02)00022-6","volume":"113","author":"P Montagna","year":"2002","unstructured":"Montagna P, Lugaresi E. Agrypnia Excitata: a generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep. Clin Neurophysiol. 2002;113:552\u201360.","journal-title":"Clin Neurophysiol"},{"key":"848_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S1474-4422(14)70157-7","volume":"13","author":"C Gaig","year":"2014","unstructured":"Gaig C, Iranzo A, Santamar\u00ed J, Dalmau J, Graus F. Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?\u2014Authors\u2019 reply. Lancet Neurol. 2014;13:864\u20135.","journal-title":"Lancet Neurol"},{"key":"848_CR22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1212\/WNL.0000000000001694","volume":"84","author":"S Baiardi","year":"2015","unstructured":"Baiardi S, Provini F, Avoni P, Pasquinelli M, Liguori R. Immunotherapy of oneiric stupor in Morvan syndrome: efficacy documented by actigraphy. Neurology. 2015;84:2457\u20139.","journal-title":"Neurology"},{"key":"848_CR23","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.sleep.2013.06.012","volume":"14","author":"O Dumitrascu","year":"2013","unstructured":"Dumitrascu O, Schenck CH, Applebee G, Attarian H. Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series. Sleep Med. 2013;14:1217\u201320.","journal-title":"Sleep Med"},{"key":"848_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-170189","volume":"59","author":"A Cagnin","year":"2017","unstructured":"Cagnin A, Mariotto S, Fiorini M, Gaule M, Bonetto N, Tagliapietra M, et al. Microglial and neuronal TDP-43 pathology in anti-IgLON5-related taupathy. J Clin Alzheimer\u2019s Dis. 2017;59:13\u201320.","journal-title":"J Clin Alzheimer\u2019s Dis"},{"issue":"1","key":"848_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","volume":"13","author":"L Sabater","year":"2016","unstructured":"Sabater L, Planagum\u00e0 J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226.","journal-title":"J Neuroinflammation"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-018-0848-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0848-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0848-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:35:13Z","timestamp":1558589713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-018-0848-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1007\/s11910-018-0848-0","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,23]]},"assertion":[{"value":"23 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Carles Gaig, Alex Iranzo, and Joan Santamaria each declare no potential conflicts of interest. Francesc Graus received a licensing fee from Euroimmun for the use of IgLON5 as an autoantibody test.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"41"}}